← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
atezolizumab
L01FF05
Forms & Strengths
- Intravenous solution: 840 mg/14 mL (60 mg/mL) single-dose vial
- Intravenous solution: 1200 mg/20 mL (60 mg/mL) single-dose vial
Adult Dosing
- Non-Small Cell Lung Cancer (NSCLC): 840 mg IV every 2 weeks, 1200 mg IV every 3 weeks, or 1680 mg IV every 4 weeks
- Small Cell Lung Cancer (SCLC): 1200 mg IV every 3 weeks in combination with carboplatin and etoposide
- Hepatocellular Carcinoma (HCC): 1200 mg IV every 3 weeks in combination with bevacizumab
- Urothelial Carcinoma: 1200 mg IV every 3 weeks
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Urothelial Carcinoma
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Hepatocellular Carcinoma (HCC)
- Melanoma (BRAF V600 mutation-negative, in combination with cobimetinib and vemurafenib)
Mechanism of Action
- Programmed death-ligand 1 (PD-L1) blocking antibody
- Prevents binding of PD-L1 to PD-1 and B7-1 receptors
- Enhances T-cell responses including anti-tumor immunity
Contraindications
- Severe hypersensitivity to atezolizumab or any of its excipients
Adverse Reactions
- Fatigue
- Musculoskeletal pain
- Cough
- Dyspnea
- Decreased appetite
- Nausea
- Immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic toxicity)
Drug Interactions
- Corticosteroids and immunosuppressants: Avoid use before starting atezolizumab due to potential interference with pharmacodynamic activity
- No formal pharmacokinetic drug-drug interaction studies have been conducted with atezolizumab
Curated Content: Needs Vetting Before Put to Clinical Use